01 / 05
Global Momentum Builds to End Female Genital Mutilation

World Health Organization | Gender Equality

Global Momentum Builds to End Female Genital Mutilation

“Interventions aimed at ending female genital mutilation over the last three decades are having an impact, with nearly two-thirds of the population in countries where it is prevalent expressing support for its elimination.

After decades of slow change, progress against female genital mutilation is accelerating: half of all gains since 1990 were achieved in the past decade reducing the number of girls subjected to FGM from one in two to one in three.”

From World Health Organization.

US Food and Drug Administration | Health & Medical Care

A Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms

“The U.S. Food and Drug Administration today approved Orzeyful (oveporexton) tablets for the treatment of narcolepsy type 1 in adults. Orzeyful is the first medicine approved for narcolepsy type 1 as a complete disorder — addressing the full range of symptoms that define the condition — and the first to work by directly targeting the loss of orexin signaling that causes the disease.”

From US Food and Drug Administration.

Zag Daily | Air Transport

DoorDash Launches Drone Airline After FAA Approval

“California-based delivery platform DoorDash has launched its own drone delivery business after securing regulatory approval to operate commercial drone services in the United States.

The company has received Federal Aviation Administration (FAA) Part 135 air carrier certification, allowing it to launch DoorDash Air, an in-house drone programme developed by its robotics division, DoorDash Labs. Alongside operating the service, DoorDash is also developing its own aircraft for local deliveries.

The approval makes DoorDash one of only a handful of drone operators in the US authorised to run commercial delivery services under its own certificate.”

From Zag Daily.

US Food and Drug Administration | Health Systems

FDA Licenses First-Ever Freeze-Dried Plasma Product in the US

“The U.S. Food and Drug Administration today licensed Ezplaz Freeze Dried Plasma (FDP), making it the first freeze-dried plasma product licensed for use in the United States. Ezplaz is intended for transfusion in adult patients who need plasma and for whom other plasma products are not available…

Unlike conventional plasma products that must be stored frozen and thawed before use, Ezplaz can be stored at room temperature, is stable after exposure to temperature fluctuations and is rapidly reconstituted. It is packaged in a plastic bag rather than a glass bottle, reducing the risk of breakage during handling and transport. FDA expects that these features will make the use of Ezplaz compatible with austere environments, potentially including combat zones, remote areas, and disaster response settings.”

From US Food and Drug Administration.